Five Prime Therapeutics to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 3

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) — Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its third quarter 2016 financial results on Thursday, November 3, 2016, after the U.S. financial markets close.  Five Prime will host a conference call and live audio webcast on Thursday, November 3, 2016, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the company’s website at www.fiveprime.com.  Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 3243563.

The archived conference call will be available on Five Prime’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company’s R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

CONTACT: Company Contact:

Heather Rowe
Investor Relations 
415-365-5737
Heather.rowe@fiveprime.com

Ads

You May Also Like

Veritas Pharma Initiates Cancer Research with Dr. Dmitri Petchkovski

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT); (OTC:VRTHF); ...

FIT Biotech Oy: Chairman of the board on leave of absence

FIT Biotech Oy                                                             Company release 16.8.2018 at 04:00 PM EET Chairman of the board ...